Department of Otorhinolaryngology-Head and Neck Surgery, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine.
Department of Therapy and Family Medicine of Postgraduate Education, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine.
J Med Life. 2022 Mar;15(3):359-361. doi: 10.25122/jml-2021-0389.
Fungal flora is one of the causes of inflammatory, including polypous, processes in the nasal cavity. In this regard, studies aimed at reducing the effect of fungal sensitization (FS) on the course of chronic polypous rhinosinusitis (CPRS) are relevant. The objective of the study was to evaluate the effect of various treatment options on the clinical course of the disease in patients with chronic polypous rhinosinusitis against the background of sensitization to fungi. The study included 90 patients with chronic polypous rhinosinusitis in combination with FS. The patients were divided into two groups - the first clinical group (G1) and the second clinical group (G2). G1 patients received allergen-specific immunotherapy (ASIT) according to the scheme. G2 patients received basic treatment. Evaluation of the clinical efficiency of ASIT was made based on complaints, assessment of symptom severity on a visual analog scale (VAS), and rhinoendoscopic examination. The treatment outcomes were evaluated on a 4-point scale, with excellent results (4 points) - complete remission of the disease during the follow-up period (6-12 months); good (3 points) - exacerbation of the disease 1-2 times a year, in mild form and removed by expectant treatment; satisfactory (2 points) - the number of exacerbations did not decrease. The use of ASIT therapy is pathogenetically justified and leads to a significant improvement in the clinical condition of patients with CPRS with FS.
真菌菌群是引起鼻腔炎症的原因之一,包括息肉状过程。因此,研究旨在减轻真菌致敏(FS)对慢性息肉状鼻窦炎(CPRS)病程的影响是相关的。本研究的目的是评估在 FS 背景下针对真菌致敏的慢性息肉状鼻窦炎患者的各种治疗选择对疾病临床病程的影响。该研究纳入了 90 例患有慢性息肉状鼻窦炎合并 FS 的患者。患者分为两组 - 第一临床组(G1)和第二临床组(G2)。G1 患者根据方案接受过敏原特异性免疫治疗(ASIT)。G2 患者接受基础治疗。根据症状评估、视觉模拟量表(VAS)评估症状严重程度和鼻内镜检查来评估 ASIT 的临床疗效。治疗结果根据以下 4 分制进行评估,优秀结果(4 分)-在随访期间(6-12 个月)疾病完全缓解;良好(3 分)-每年疾病恶化 1-2 次,呈轻度且通过预期治疗缓解;满意(2 分)-恶化次数未减少。ASIT 治疗的使用在发病机制上是合理的,并导致 FS 慢性息肉状鼻窦炎患者的临床状况显著改善。